Posted by Michael Wonder on 20 Nov 2020
Lumicell granted fast track designation approval by the FDA for breast cancer treatment
18 November 2020 - Fast track designation augments previously granted breakthrough device designation.
Lumicell today announced it has received fast track designation with rolling review from the FDA Center for Drug Evaluation and Research to expedite the development and review of the LUM imaging system in the treatment of breast cancer.
